Katalog Plus
Bibliothek der Frankfurt UAS
Bald neuer Katalog: sichern Sie sich schon vorab Ihre persönlichen Merklisten im Nutzerkonto: Anleitung.
Dieses Ergebnis aus BASE kann Gästen nicht angezeigt werden.  Login für vollen Zugriff.

An open label study on Depression Patient's Disability Outcomes: Comparative Evaluation of Escitalopram and Amisulpride

Title: An open label study on Depression Patient's Disability Outcomes: Comparative Evaluation of Escitalopram and Amisulpride
Authors: Kaul, Vijay; Dutta, Shaktibala; Beg, Mirza Atif; Singh, Nand Kishore; Bawa, Shalu; Anjoom, Mohammed; Dutta, Srihari; Rai, Prithi
Source: Journal of Nobel Medical College; Vol. 5 No. 2 (2016); 37-42 ; 2091-234X ; 2091-2331
Publisher Information: Research and Publication Unit of Nobel Medical College
Publication Year: 2016
Collection: Nepal Journals Online (NepJOL)
Subject Terms: Depression; Amisulpride; Escitalopram; WHO Disability Assessment Schedule (WHO-DAS)
Description: Background Depression is an important global public health problem due to its relatively high lifetime prevalence and significant disability caused by it. The present study was conducted to compare improvement in disability outcome by Amisulpride and Escitalopram among depression patients using WHO-Disability Assessment Schedule (WHO-DAS).Materials and Methods The study was conducted in depression patients for 1 year in the Department of Neuropsychiatry, Nepalgunj Medical College & Teaching Hospital. A total of 117 depression patients were divided into 2 groups. Group I (58 patients) received Amisulpride tablet at a dose of 50 mg/day and Group II (59 patients) were given Escitalopram at a dose of 10 mg/day. The patients were required to follow up at 4 weeks, 8 weeks and at 15 weeks. The efficacy of the drugs was calculated by Hamilton depression rating scale (HAM-D). The improvement in functional outcome was compared between the two groups by using WHO-Disability Assessment Schedule (WHO-DAS). Appropriate statistical tools using GraphPadInstat 3.0 were used for analysis. p value < 0.05 was considered significant.Results HAM-D score in group receiving Amisulpride at 0 and 15 weeks was 16.92±0.35 and 7.87±0.29 (p
Document Type: article in journal/newspaper
File Description: application/pdf
Language: English
Relation: https://nepjol.info/index.php/JoNMC/article/view/16315/13224; https://nepjol.info/index.php/JoNMC/article/view/16315
Availability: https://nepjol.info/index.php/JoNMC/article/view/16315
Rights: Copyright (c) 2016 Journal of Nobel Medical College
Accession Number: edsbas.98F910A7
Database: BASE